AKT1 and acute myeloid leukemia: These findings demonstrate that Akt inhibition enhances, whereas Akt activation diminishes, the apoptotic effects of venetoclax–HMA co-treatment, indicating that suppression of Akt signaling facilitates venetoclax sensitization in resistant AML cells.